Transcatheter Aortic Valve Replacement (TAVR) Market Research Report By Procedure Type (Self-Expanding Valve, Balloon-Expandable Valve, Transcatheter Aortic Valve), By Reference Type (Direct Access, Transfemoral, Transapical), By Material Type (Metal, Bioprosthetic, Hybrid), By End-user (Hospitals, Cardiac Centers, Ambulatory Surgical Centers), and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

Transcatheter Aortic Valve Replacement Market Summary

As per MRFR analysis, the Transcatheter Aortic Valve Replacement (TAVR) Market was valued at 5.26 USD Billion in 2023 and is projected to grow to 12 USD Billion by 2035. The market is driven by the increasing prevalence of aortic stenosis, particularly among the aging population, and advancements in transcatheter technologies that enhance safety and efficacy. The shift towards minimally invasive procedures is also contributing to market growth, as patients prefer options that reduce recovery times and hospital stays.

Key Market Trends & Highlights

The TAVR market is witnessing significant trends driven by demographic changes and technological advancements.

• Market Size in 2024: 5.64 USD Billion; projected to reach 12 USD Billion by 2035.
• CAGR from 2025 to 2035: 7.11%; driven by rising aortic stenosis cases.
• Self-Expanding Valve segment projected to grow from 2.37 USD Billion in 2024 to 5.08 USD Billion by 2035.
• Transfemoral method is preferred for its minimally invasive nature, enhancing recovery.

Market Size & Forecast

2023 Market Size: 5.26 USD Billion

2024 Market Size: 5.64 USD Billion

2035 Market Size: 12 USD Billion

CAGR (2025-2035): 7.11%

Largest Regional Market Share in 2024: North America.

Major Players

Key Companies include Tendyne, Abbott Laboratories, CryoLife, Edwards Lifesciences, LivaNova, Medtronic, and Boston Scientific.

Key Transcatheter Aortic Valve Replacement (TAVR) Market Trends Highlighted

The growing incidence of aortic stenosis in the elderly population is propelling notable developments in the Transcatheter Aortic Valve Replacement (TAVR) Market. More broad use is being encouraged by the rising demand for minimally invasive therapies among patients and healthcare professionals, since TAVR procedures provide less invasive choices than standard surgery.

Further improving the efficacy and safety of these operations and making them appropriate for a wider spectrum of patients are technical developments in valve design and delivery systems. Additionally, there is a definite chance to increase the use of TAVR in low-risk patients, which was previously a barrier preventing its widespread usage.

More healthcare facilities are probably going to adopt TAVR as standard practice as the body of clinical data demonstrating its efficacy in this population keeps expanding. Additionally, the growing number of clinical studies conducted worldwide is probably going to result in the approval of new devices with better characteristics, which will boost the market environment.

The availability of sophisticated TAVR technology is being aided by the current trend of rising healthcare costs in various parts of the world. Initiatives and financing programs targeted at enhancing heart valve treatments are a result of governments and health organizations realizing the significance of tackling cardiovascular disorders.

To further spur market innovation, regulatory bodies are also expediting the approval procedures for new TAVR technologies. Modernization and more patient access to life-saving operations are expected to boost the global TAVR market as these trends continue to develop.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Transcatheter Aortic Valve Replacement (TAVR) Market Drivers

Growing Prevalence of Aortic Stenosis

The Transcatheter Aortic Valve Replacement (TAVR) Market is experiencing significant growth due to the increasing prevalence of aortic stenosis among the aging population. According to the American College of Cardiology, approximately 5% of the elderly population over the age of 75 years suffers from aortic stenosis.

This statistic underscores the critical need for effective treatment options such as TAVR, as traditional surgical aortic valve replacement may not be suitable for all patients, particularly due to age or comorbid conditions. The Global demographic shift towards an older population emphasizes the necessity for advanced cardiovascular treatments.

Furthermore, organizations like the American Heart Association are actively promoting awareness regarding the treatment of heart diseases and conditions like aortic stenosis, thereby facilitating increased patient access to TAVR procedures and fueling market growth.

The consistent rise in cardiovascular-related health issues further supports the demand for innovative, less invasive solutions such as Transcatheter Aortic Valve Replacement.

Technological Advancements in TAVR

Innovations in device technology are propelling the Transcatheter Aortic Valve Replacement (TAVR) Market forward. Recent developments in TAVR valves, such as improved delivery systems and enhanced valve durability, have made procedures safer and more effective.

For instance, a study presented at the European Society of Cardiology found that next-generation TAVR devices have shown up to a 30% reduction in complications compared to earlier models.

Furthermore, endorsements from reputable organizations like the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for newer TAVR technologies enhance patient and physician trust in these devices. As these technological advancements continue, they are expected to significantly drive market adoption and usage across Global healthcare systems.

Increased Regulatory Approvals and Reimbursements

Favorable regulatory environments and improved reimbursement policies are key drivers in the Transcatheter Aortic Valve Replacement (TAVR) Market. Recent updates from multiple healthcare reimbursement authorities globally have led to broader coverage for TAVR procedures, aligning with the growing recognition of its clinical benefits.

For example, the Centers for Medicare & Medicaid Services (CMS) in the United States announced policy changes that enhance reimbursement rates for TAVR, which is expected to result in a significant increase in procedure volumes.

This positive stance on reimbursement not only alleviates financial barriers for patients but also encourages healthcare providers to adopt TAVR as a standard treatment option, ensuring the further expansion of the market.

Rising Demand for Minimally Invasive Procedures

The shift towards minimally invasive treatment options is transforming the Transcatheter Aortic Valve Replacement (TAVR) Market. Patients are increasingly favoring procedures that promise quicker recovery times and lower risks of complications.

Data from the World Health Organization indicates that minimally invasive surgical techniques have grown in popularity, with more than 60% of cardiac surgeries now opting for less invasive options.

This trend aligns with the increasing patient demand for safer procedures, and organizations like the European Society of Cardiology are endorsing the benefits of TAVR as a less invasive alternative to traditional aortic valve surgery. Such recommendations promote wider acceptance and utilization of TAVR, thereby propelling market growth in the Global landscape.

Transcatheter Aortic Valve Replacement (TAVR) Market Segment Insights

Transcatheter Aortic Valve Replacement (TAVR) Market Procedure Type Insights

The Transcatheter Aortic Valve Replacement (TAVR) Market was diversified into three primary Procedure Type categories, namely Self-Expanding Valve, Balloon-Expandable Valve, and Transcatheter Aortic Valve, each contributing significantly to overall market dynamics.

In 2024, the Self-Expanding Valve segment was valued at 2.1 USD Billion, making it a notable portion of the market, driven mainly by its advantages such as ease of implantation and adaptability to various anatomies, garnering the majority holding within the market.

The Balloon-Expandable Valve segment followed with a valuation of 1.8 USD Billion, appealing due to its consistent performance in valve expansion and reliable hemodynamic outcomes, which enhanced its adoption and made it a critical player in heart valve interventions.

The Transcatheter Aortic Valve segment, valued at 1.74 USD Billion in 2024, exemplified a robust solution for patients with aortic stenosis, providing a minimally invasive option that reduces recovery time and improves surgical outcomes.

As the TAVR market continues to evolve, these Procedure Type segments reflected diverse approaches to addressing heart valve diseases and showed varying growth trajectories and clinical preferences among healthcare providers. Factors such as increasing geriatric populations globally, the rising prevalence of aortic stenosis, and advancements in valve technology are contributing to market growth.

Each Procedural Type held unique advantages, with the Self-Expanding Valve demonstrating a significant impact on procedural efficiency and patient outcomes.

Additionally, as the Transcatheter Aortic Valve Replacement (TAVR) Market statistics revealed, industry trends indicate an increasing preference for minimally invasive techniques, enhancing the relevance of these segments in the global healthcare landscape and emphasizing their growth opportunities in light of an aging demographic with higher incidence rates of heart-related ailments.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Transcatheter Aortic Valve Replacement (TAVR) Market Reference Type Insights

The Transcatheter Aortic Valve Replacement (TAVR) Market, specifically within the Reference Type segment, is poised for notable growth, driven by an increasing patient population and advancements in medical technology.

Among the varied access routes for valve deployment, the transfemoral approach has gained substantial favor due to its less invasive nature and lower complication rates, thus dominating the market. In contrast, the transapical method serves as a significant alternative, particularly for patients with unsuitable femoral access, reflecting the segment's flexibility to cater to diverse clinical scenarios.

Direct access remains a notable strategy as well, especially in specific clinical settings. The ongoing innovations in delivery systems and materials are set to enhance procedural outcomes across all access types, leading to an improved patient experience and expanding the market's reach.

Overall, the evolving landscape of the Transcatheter Aortic Valve Replacement (TAVR) Market segmentation underscores the importance of these access methods in ensuring effective treatment for aortic valve diseases.

Transcatheter Aortic Valve Replacement (TAVR) Market Material Type Insights

In the Transcatheter Aortic Valve Replacement (TAVR) Market, the Material Type segment plays a crucial role in defining the performance and efficacy of the devices used in treatment. This segment is composed of various materials including Metal, Bioprosthetic, and Hybrid designs, each serving unique functions and catering to different patient needs.

Metal valves, known for their durability, are commonly preferred for patients with longer life expectancies, making them a significant choice in the market. On the other hand, Bioprosthetic valves, often made from animal tissues, tend to be favored for older patients due to reduced anticoagulation requirements, thus holding a prominent position in global sales.

Hybrid options, which combine features from both metal and bioprosthetic materials, are gaining traction as they aim to offer the benefits of each type, addressing specific clinical challenges. The continuous innovation and expansion in these materials are driven by the increasing prevalence of heart diseases worldwide, underlined by statistics showcasing a growing demand for less invasive surgical options.

The Transcatheter Aortic Valve Replacement (TAVR) Market revenue is also supported by ongoing advancements in technology and an aging population, positioning the Material Type segment as pivotal in enhancing patient outcomes and driving overall market growth.

Transcatheter Aortic Valve Replacement (TAVR) Market End-user Insights

The End-user segment is a critical component of this growth, comprised of various healthcare settings including hospitals, cardiac centers, and ambulatory surgical centers. Hospitals play a pivotal role, offering advanced cardiac care and facilitating complex procedures, thus dominating the market.

Cardiac centers provide specialized care and expertise in managing patients with aortic stenosis, which enhances the overall patient experience and outcomes. Ambulatory surgical centers are also emerging as significant contributors, as they offer less invasive procedures and quicker recovery times, appealing to a growing patient preference for outpatient options.

The increasing geriatric population and rising prevalence of heart diseases are key growth drivers for the Transcatheter Aortic Valve Replacement (TAVR) Market, creating opportunities for all End-users to expand their services.

Market trends show a shift towards minimally invasive techniques and improved patient management, driving innovation and expanding the Transcatheter Aortic Valve Replacement (TAVR) Market revenue across regions.

Challenges include regulatory hurdles and the need for skilled professionals to perform these advanced procedures. Nonetheless, the segmentation across hospitals, cardiac centers, and ambulatory surgical centers reflects the diverse healthcare landscape and the growing demand for effective aortic valve replacement solutions globally.

Transcatheter Aortic Valve Replacement (TAVR) Market Regional Insights

The Transcatheter Aortic Valve Replacement (TAVR) Market attained significant value across various regions, with North America holding the majority share. In 2024, North America was valued at 3.06 USD Billion, and it is expected to grow to 6.43 USD Billion by 2035.

Europe followed closely with a valuation of 1.86 USD Billion in 2024, anticipated to reach 3.94 USD Billion in 2035, driven by advanced healthcare infrastructure and rising awareness among patients. South America showed a modest valuation of 0.20 USD Billion in 2024, expected to grow to 0.43 USD Billion by 2035, largely influenced by the increasing prevalence of aortic stenosis.

The Asia Pacific region was valued at 0.88 USD Billion in 2024 and expected to increase to 1.87 USD Billion by 2035 as countries in this region enhance their healthcare systems. The Middle East and Africa accounted for 0.64 USD Billion in 2024, with growth prospects leading to 1.33 USD Billion in 2035, reflecting investments in cardiac care.

Overall, the Transcatheter Aortic Valve Replacement (TAVR) Market showcased distinct regional dynamics, with each area contributing uniquely to the growing demand for minimally invasive heart procedures.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Transcatheter Aortic Valve Replacement (TAVR) Market Key Players and Competitive Insights

The Transcatheter Aortic Valve Replacement (TAVR) Market has been experiencing significant growth due to the rising prevalence of aortic stenosis and the need for minimally invasive surgical procedures. As more healthcare providers recognize the benefits of TAVR, competition among key players has intensified.

The market landscape is characterized by a mix of established manufacturers and emerging companies, all striving to enhance their product offerings and expand their clinical indications. Companies are focusing on innovation in valve design, delivery systems, and procedural techniques, which are crucial for improving patient outcomes and gaining market share.

Additionally, strategic collaborations and partnerships have become common as companies aim to enhance their technological capabilities and geographical reach in a rapidly evolving market.

Edwards Lifesciences has established itself as a leading player in the Transcatheter Aortic Valve Replacement (TAVR) Market, primarily through its innovative product offerings tailored for patients with aortic valve diseases.

The company has a strong global presence, with a wide distribution network that enables it to reach diverse markets effectively. One of its notable strengths is the continuous investment in research and development, which has led to advanced products characterized by improved safety and effectiveness profiles.

Edwards Lifesciences' commitment to clinical education and post-market studies further enhances its credibility and supports its market leadership position, allowing the company to maintain a competitive edge as healthcare professionals increasingly adopt TAVR technologies.

CryoLife, while primarily known for its contributions to the cardiac and vascular surgical fields, is making inroads into the Transcatheter Aortic Valve Replacement (TAVR) Market through strategic initiatives and product innovation.

The company focuses on delivering high-quality heart valve therapies and has expanded its portfolio to include TAVR solutions aimed at improving patient outcomes. With its dedication to advancing minimally invasive procedures, CryoLife is well-positioned to capitalize on the growing demand for TAVR.

The company's strengths lie in its robust manufacturing capabilities, commitment to product safety, and strategic partnerships that enhance its market offering. As part of its growth strategy, CryoLife has pursued mergers and acquisitions that bolster its ability to deliver comprehensive cardiac solutions on a global scale, thereby enhancing its competitiveness within the TAVR market.

Key Companies in the Transcatheter Aortic Valve Replacement (TAVR) Market Include

• Edwards Lifesciences


• CryoLife


• Micro Interventional Devices


• Biosense Webster


• Sahajanand Medical Technologies


• Medtronic


• Johnson & Johnson


• Abbott Laboratories

Transcatheter Aortic Valve Replacement (TAVR) Market Developments

The transcatheter aortic valve replacement (TAVR) area is moving forward quickly, with key changes in regulations and new products that make treatments easier to access and more precise.

In a major regulatory update, the U.S. FDA approved in May 2025 the use of Edwards Lifesciences’ SAPIEN 3, SAPIEN 3 Ultra, and Ultra RESILIA valves for patients with severe aortic stenosis who do not show symptoms. This represented the inaugural TAVR approval for asymptomatic patients, substantiated by favorable results from the EARLY TAVR trial. The initiative aims to expand the treatment scope by targeting severe aortic stenosis at earlier stages.

In March 2024, Medtronic attained a significant milestone with the FDA's approval of its Evolut FX+ TAVR system. The device features a restructured frame that includes considerably larger coronary access windows, which improve deliverability and procedural visibility, all while ensuring strong valve performance. This advancement seeks to tackle challenges related to coronary access, particularly in younger and low-risk patients who are likely to need future coronary interventions.

In May 2025, Medtronic obtained CE mark approval for the Evolut Pro+ and Evolut FX platforms, thereby broadening treatment options in Europe for redo-TAVR procedures. The approvals facilitate valve-in-valve procedures for instances of failing previously implanted TAVR valves, thereby providing clinicians with enhanced flexibility in the management of complex structural heart cases.

These innovations demonstrate the increasing sophistication and clinical integration of TAVR systems, as manufacturers emphasize earlier intervention, improved anatomical access, and long-term treatment strategies, particularly for younger and lower-risk patient groups.

Transcatheter Aortic Valve Replacement (TAVR) Market Segmentation Insights

Transcatheter Aortic Valve Replacement (TAVR) Market Procedure Type Outlook

• Self-Expanding Valve


• Balloon-Expandable Valve


• Transcatheter Aortic Valve

Transcatheter Aortic Valve Replacement (TAVR) Market Reference Type Outlook

• Direct Access


• Transfemoral


• Transapical

Transcatheter Aortic Valve Replacement (TAVR) Market Material Type Outlook

• Metal


• Bioprosthetic


• Hybrid

Transcatheter Aortic Valve Replacement (TAVR) Market End-user Outlook

• Hospitals


• Cardiac Centers


• Ambulatory Surgical Centers

Transcatheter Aortic Valve Replacement (TAVR) Market Regional Outlook

• North America


• Europe


• South America


• Asia Pacific


• Middle East and Africa

Report Attribute/Metric	Details
Market Size 2023	5.26(USD Billion)
Market Size 2024	5.64(USD Billion)
Market Size 2035	12.0(USD Billion)
Compound Annual Growth Rate (CAGR)	7.1% (2025 - 2035)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Edwards Lifesciences, CryoLife, Micro Interventional Devices, Biosense Webster, Sahajanand Medical Technologies, Medtronic, Johnson & Johnson, Abbott Laboratories
Segments Covered	Procedure Type, Reference Type, Material Type, End-user, Regional
Key Market Opportunities	Aging population demands TAVR solutions, Advances in minimally invasive techniques, Increasing prevalence of aortic stenosis, Growing healthcare expenditure globally, Expanding market in emerging economies
Key Market Dynamics	minimally invasive procedure demand, aging population increase, technological advancements in devices, rising prevalence of aortic stenosis, favorable reimbursement policies
Countries Covered	North America, Europe, APAC, South America, MEA